Diethylenetriaminepentaacetic acid (DTPA)

Diethylenetriaminepentaacetic acid (DTPA), also known as pentetic acid, is a synthetic aminopolycarboxylic acid that functions as a powerful chelating agent with a high affinity for metal cations. It is clinically utilized as a decorporation agent, typically in the form of calcium or zinc salts (Ca-DTPA or Zn-DTPA), to treat internal contamination with radioactive actinides such as plutonium, americium, and curium by forming stable, water-soluble complexes that are excreted via the kidneys. In the field of oncology, DTPA is employed as a hapten in pre-targeted radioimmunotherapy strategies, such as the Affinity Enhancement System (AES). In this context, a bivalent "di-DTPA hapten" (e.g., IMP-192) serves as the target for bispecific antibodies that have been pre-localized to tumor-associated antigens, such as carcinoembryonic antigen (CEA). This approach allows for the precise delivery of radionuclides to tumor sites, significantly improving the tumor-to-background ratio and reducing systemic toxicity compared to directly radiolabeled antibodies. Additionally, DTPA derivatives like gadopentetate dimeglumine are widely used as contrast agents in magnetic resonance imaging (MRI), and modified versions like tiuxetan are used to link radionuclides to therapeutic antibodies.

Other names

Pentetic acidDiethylenetriamine pentaacetatedi-DTPA haptenDTPA-indium haptenPentaceaIMP-192PendetideTiuxetan

DTPA acts as a polydentate chelator that sequesters metal ions into stable, water-soluble complexes for renal excretion. In pre-targeted radioimmunotherapy, the di-DTPA hapten functions as a bivalent ligand that cross-links bispecific antibodies at the tumor site, enhancing retention and localization of radiopharmaceuticals.